Clearside Biomedical, Inc.
Clearside Biomedical, Inc. (CLSDQ): 20 pipeline candidates · 3 upcoming catalysts · ~4 mo cash runway · 14 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.0 months
D/E -1.22 · 0% dilution
Lead: Phase 3
20 candidates
3 upcoming, next in ~340d
N/A
A transparent, data-derived signal for Clearside Biomedical, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$576K
Cash
$6.8M
Quarterly Burn
$5.5M
Runway
4.0 mo
Revenue
$201K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (20 candidates)
| Drug | Phase |
|---|---|
| ARVN001 (Arcatus) | Phase 3 |
| ARVN011 | Phase 1 |
| CLS-AX | Phase 2 |
| Dupilumab | Phase 4 |
| Honey in orabase 1 | Phase 2 |
| Hydrocortisone | Phase 4 |
| JNJ-81201887 | Phase 2 |
| Ketorolac | Phase 3 |
| Lidocaine | Phase 4 |
| standard neoadjuvant chemotherapy regimens | Phase 2 |
Showing 10 of 20 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Frequently asked questions
How many drug candidates are in Clearside Biomedical, Inc.'s pipeline?
Clearside Biomedical, Inc. (CLSDQ) has 20 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Clearside Biomedical, Inc.'s lead drug candidate?
Clearside Biomedical, Inc.'s most advanced tracked candidate is ARVN001 (Arcatus) (Phase 3) for uveitic macular edema.
What is Clearside Biomedical, Inc.'s next catalyst?
Clearside Biomedical, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ACULAR LS" — expected May 24, 2027.
What is Clearside Biomedical, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Clearside Biomedical, Inc. has approximately 4.0 months of cash runway.
What is Clearside Biomedical, Inc.'s market capitalization?
Clearside Biomedical, Inc.'s market capitalization is approximately $576K.
Get the full picture on Clearside Biomedical, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.